Hypoaldosteronism epidemiology and demographics

Hypoaldosteronism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypoaldosteronism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypoaldosteronism epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hypoaldosteronism epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypoaldosteronism epidemiology and demographics
CDC on Hypoaldosteronism epidemiology and demographics
Hypoaldosteronism epidemiology and demographics in the news
Blogs on Hypoaldosteronism epidemiology and demographics
Directions to Hospitals Treating Hypoaldosteronism
Risk calculators and risk factors for Hypoaldosteronism epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Epidemiology and Demographics

Incidence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
• The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Age

• Hypoaldosteronism is most commonly seen in middle-aged and older individuals.
• Elderly patients on multiple drug therapy (polypharmacy) have an increased incidence of drug induced hypoaldosteronism.
• In younger patients, hypoaldosteronism is seen in patients with underlying diabetes mellitus type I or sickle cell disease.

Race

• Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.

Gender

• Hypoaldosteronism affects both men and women equally.